3.5 Publications

April 3, 2021

Early Introductions and Transmission of SARS-CoV-2 Variant B.1.1.7 in the United States

Cell, Tempus-authored — The emergence and spread of SARS-CoV-2 lineage B.1.1.7, first detected in the United Kingdom, has become a global public health concern because of its increased transmissibility. Over 2,500 COVID-19 cases associated with this variant have been detected in the United States (US) since December 2020, but the extent o...

March 17, 2021

Non-secretory Multiple Myeloma With Unusual TFG-ALK Fusion Showed Dramatic Response to ALK Inhibition

npj Genomic Medicine, Tempus-authored — Non-secretory multiple myeloma (NSMM) constitutes a distinct entity of multiple myeloma characterized by the absence of detectable monoclonal protein and rarely an absence of free light chains in the serum and urine. Given its rarity, the genomic landscape, clinical course, and prognosis of NSSM are...

March 10, 2021

Transferring Diagnostic and Prognostic Molecular Models Across Technological Platforms

AACR Annual Meeting 2021, Tempus-authored — The reproducibility of results obtained using RNA data across labs is a major hurdle in cancer research. Difference in library preparation methods and gene expression quantification platforms prevent the application of trained models to new data across labs. SpinAdapt is a novel unsupervised domain ada...

March 10, 2021

Incidence of Molecular Alterations in KRAS and Other Known Cancer Genes in Patients With Pancreatic Cancer Assessed With a Commercial Genomic Profiling Panel Compared to TCGA Results

AACR Annual Meeting 2021, Tempus-authored — Background: The Cancer Genome Atlas (TCGA) characterizes somatic mutations of pancreatic cancer (PC) patients (pts) using whole-exome sequencing (WES, mean coverage 405x) of fresh frozen tumor tissues and matched blood samples. In addition, it includes a confirmation of the key genomic findings by a targe...

March 10, 2021

Characterizing Differences in Checkpoint Inhibitor Biomarkers in a Real-world Cohort of Stage III and IV Non-small Cell Lung Cancer Patients

AACR Annual Meeting 2021, Tempus-authored — Immune checkpoint blockade (ICB) therapies have emerged as an essential treatment modality in lung cancer. While ICB therapies are approved in several indications for stage IV and metastatic non-small cell lung cancers (NSCLC), approvals for early but invasive tumors have been limited. To investigate the...

March 10, 2021

Genomic Characterization and Monitoring Molecular Response to Treatment in African American (AA) Advanced Prostate Cancer (PC) Patients (Pts) via Next-Generation Sequencing (NGS): Real-world Experience in a Safety Net Hospital Oncology Clinic

AACR Annual Meeting 2021, Tempus-authored — Background: AA men have higher PC incidence and mortality than white men. Healthcare access and other socioeconomic factors contribute to these disparities. The high cost of NGS can become an additional factor for disparity. Indeed, minority and uninsured pts were underrepresented in prior NGS...

March 10, 2021

Evaluating Clinical Features and Prognostic Factors Associated With Response to Immune Checkpoint Blockade in mNSCLC Patients

AACR Annual Meeting 2021, Tempus-authored — In the past decade, immune checkpoint blockade (ICB) has become standard of care for patients with metastatic non-small cell lung cancer (mNSCLC). Biomarkers of response to ICB, such as PD-L1 status, help identify suitable candidates for ICB. However, differences in the underlying clinical features...

March 10, 2021

Comprehensive Validation of RNA Sequencing for Clinical NGS Fusion Genes and RNA Expression Reporting

AACR Annual Meeting 2021, Tempus-authored — Tumor genome sequencing has emerged as a powerful tool for identifying biomarkers for targeted cancer therapies. While DNA sequencing is a well-established method and considered a gold standard, RNA sequencing (RNA-seq) can identify anomalies in gene transcription, regulation of gene expression, and gene fusions, whi...

March 10, 2021

Cytotoxic CD4+ T Cells Contribute to Anti-tumor Immune Responses in NSCLC

AACR Annual Meeting 2021, Tempus-authored — Immune checkpoint blockade (ICB) is widely used to treat non-small cell lung cancer (NSCLC) patients and works by inhibiting the PD-1/PDL1 axis to reinvigorate exhausted T cells. In the prevailing model, the primary mechanism for direct tumor cell killing occurs through cytotoxic CD8+ T c...

March 10, 2021

Leveraging RNA Sequencing for Scalable Tumor Immune Repertoire Profiling

AACR Annual Meeting 2021, Tempus-authored — Background: Therapeutic strategies that modulate the interaction between tumors and tumor-infiltrating lymphocytes (TILs), such as checkpoint blockade, have tremendous promise but yield clinical responses in only a subset of patients. Accumulating evidence indicates that better characterizing TILs using repertoire-sequencing (rep-seq) may aid in predict...

Show More